Jenscare Scientific Co. Ltd. has released its interim results for the first half of 2025, reporting a total revenue of US$ 3.6 million. The company recorded a gross profit of US$ 1.7 million and a sales profit of US$ 1.1 million, achieving a gross profit margin close to 90% and a sales profit margin close to 60%. Jenscare reported an adjusted non-IFRS loss of US$ 12.9 million, which marks a decrease of approximately 3% compared to the first half of 2024. The net cash used in operating activities was US$ 13 million, reflecting a decrease of around 15% from 2024H1. In terms of cash resources, the company reported cash and cash equivalents, term deposits, and financial assets amounting to US$ 84.6 million. The net loss per share attributable to ordinary shareholders, both basic and diluted, was US$ 0.06. Significant developments in Jenscare's business operations include key advancements in their product portfolio. The registration application for JensClip, a TMVr system, has been submitted to the NMPA and is now in the registration stage. The globalization process of JensClip is progressing with pre-commercialization implantations overseas showing excellent performance, and CE Marking activities are underway. For the LuX-Valve Series, the TTVR system in China has entered the long-term follow-up phase of its multicenter clinical trial for NMPA approval, while in Europe, the LuX-Valve Plus has completed a 6-month follow-up of the TRINITY study and is under registration review. In the U.S., the IDE Early Feasibility Study of LuX-Valve Plus has completed subject enrollment and received reimbursement from CMS. Ken-Valve, a TAVR system, has gained market access in China following NMPA approval, and commercialization activities are progressing smoothly with hospital adoption.